Cocrystal Pharma Provides Update on Influenza A Program
19 oct. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...